ALEC - Alector, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
20.73
+0.95 (+4.80%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close19.78
Open19.75
Bid0.00 x 800
Ask25.00 x 1300
Day's Range18.94 - 21.99
52 Week Range18.00 - 21.99
Volume530,142
Avg. Volume2,730,500
Market Cap1.417B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Opening Bell, February 7, 2019
    CNBC Videos13 days ago

    Opening Bell, February 7, 2019

    Ringing today's opening bells are Cycle for Survival with Equinox President Scott Rosen at the NYSE and Alector with CEO Arnon Rosenthal at the Nasdaq.

  • Today's Bell Ringer, February 7, 2019
    CNBC Videos13 days ago

    Today's Bell Ringer, February 7, 2019

    Today's bell ringers are Cycle for Survival with Equinox President Scott Rosen at the NYSE and Alector with CEO Arnon Rosenthal at the Nasdaq.

  • IPO Market Momentum Gains Speed, Fueled By Biotech Sector
    Investor's Business Daily9 days ago

    IPO Market Momentum Gains Speed, Fueled By Biotech Sector

    The IPO market is expected to show another uptick in volume this week as six initial public offerings are set to price and raise $882.6 million in proceeds. It follows three IPOs last week.

  • $70M IPO planned by Santa Clara startup with sonic treatment for cardiovascular disease
    American City Business Journals9 days ago

    $70M IPO planned by Santa Clara startup with sonic treatment for cardiovascular disease

    ShockWave has raised about $150 million in funding from investors who include Venrock, T. Rowe Price, Sectoral Asset Management, Sofinnova Capital and Fidelity.

  • GlobeNewswire13 days ago

    Nasdaq Welcomes Alector, Inc. (Nasdaq: ALEC) to the Nasdaq Stock Market

    Alector, Inc. (ALEC), a clinical stage biotechnology company, rang the Nasdaq MarketSite bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market. Alector is pioneering immuno-neurology, a novel therapeutic approach to counteract the multiple pathologies that cause degenerative brain disorders by restoring healthy immune function to the brain. Supporting its scientific approach, the Company’s Discovery Platform enables them to advance a broad portfolio of product candidates, validated by human genetics, which they believe will improve the probability of technical success of these product candidates and shorten the development timelines to bring these therapies to patients.

  • MarketWatch13 days ago

    Alector's stock opens below IPO price, then swings above it

    Shares of newly public biopharmaceutical company Alector Inc. opened just shy of its initial public offering price, before swinging slightly higher in morning trade. The first trade was at $18.70 for about 542,000 shares at 10:39 Eastern, which was 1.6% below the $19 IPO price. The stock was last trading 0.5% above its IPO price. The stock is listed on Nasdaq under the ticker symbol "ALEC." The company has gone public at a time when the iShares Nasdaq Biotechnology ETF has lost 2.1% over the past three months, while the Renaissance IPO ETF has gained 1.2% and the S&P 500 has declined 3.6%.

  • MarketWatch13 days ago

    Biopharma company Alector prices IPO at $19, midpoint of price range

    Biopharmaceutical company Alector Inc. priced its initial public offering at $19 a share, the midpoint of its $18 to $20 range, according to Nasdaq. The company sold 9.25 million shares to raise $175.8 million. Shares will start trading on Nasdaq later Thursday, under the ticker symbol "ALEC".

  • Business Wire13 days ago

    Alector Announces Pricing of Initial Public Offering

    Alector, Inc. , a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per share.

  • Benzinga17 days ago

    IPO Outlook For The Week: Biotechs And Blank Checks

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Alector, Inc. (ALEC) will issue 9.25 million shares between $18 and $20 ...